To date, there has been no effective antiviral drug for any known coronavirus.
Soligenix, Inc. announced that the US National Institute of Allergy and Infectious Diseases exercised its option for the evaluation of their ricin vaccine to fund animal efficacy studies.
Researchers developed a new technique for investigating the effects of gene deletion at the later stages in the life cycle of a parasite that causes malaria in rodents.
The vaccine targets the four most common strains of PEDv found in North America.
This video gives an overview of Dengue and the related public health challenges.
The synthetic ubiquitin variants (UbVs) eliminated Middle East respiratory syndrome (MERS) from cells within 24 hours. The researchers also created UbVs that blocked the Crimean-Congo virus.
There has been a decline in production of one of the only diphtheria drugs because there is no financial incentive or market for pharmaceutical companies to produce it.
SIGA Technologies, Inc. recently completed the enrollment and dosing of subjects in a clinical study of an intravenous formulation intended for the treatment of smallpox and related orthopoxvirus infections.
Cohort quarantine may have limited community spread, but transmission occurred among members of the hospital cohort quarantined together.
Investigators are searching for ways to prevent the coronavirus from attaching to DPP-4 receptors.